U.S. Patent No.
10,961,307 (Methods of Treating Moderately to Severely Active Ulcerative Colitis by Administering an Anti-IL12/IL23 Antibody)
Patent Owner
Janssen Biotech, Inc.
Petitioner(s)
Biocon Biologics Inc.; Biocon Biologics Limited; Biocon Biologics UK Limited; Biocon Limited
§ 102 Challenge
Y: Claims 1-4, 6-22, 24-34
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Terminated Prior to Institution Decision
§ 103 challenge
Y: Claims 1-34
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Terminated Prior to Institution Decision
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled Prior to Institution Decision)
IPR Status
Settled Prior to Institution Decision